Table 1.
Summary of studies on the effects and mechanisms of light on pain.
Color | Study | Subjects | Route | Exposure | Intensity/ Irradiance | Pain Condition | Δ Pain | Mechanism of Action |
---|---|---|---|---|---|---|---|---|
White 390–740nm | Kowacs et al. 200151 | Human | Visual | 2 sec | 50–20,000 lux | Migraine | ↑ | ↓ trigeminal + cervical pain thresholds |
Dolgonos et al. 201121 | Rat | Visual | 9 min | 9.1 × 103 μW/cm2 | - | ↑ | Intraretinal trigeminal sensitization | |
Leichtfried et al. 201459 | Human | Visual | 6 hr | 5000 lux | Chronic nonspecific back pain | ↓ | - | |
Martenson et al. 201666 | Rat | Visual | 30 sec | 18,000 lux | Fibromyalgia | ↑ | Visual system → OPN → RVM | |
Noseda et al. 201676 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway | |
Burgess et al. 201710 | Human | Visual | 1 hr | 3000+ lux | Fibromyalgia | ↓ | Dim light melatonin onset shift | |
Nir et al. 201875 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway | |
Burgess et al. 201911 | Human | Visual | 1 hr | 3000+ lux | Chronic LBP | ↓ | Dim light melatonin onset shift | |
Burns et al. 202012 | Human | Visual | 1 hr | 3000+ lux | Chronic LBP | ↓ | - | |
Bumgarner et al. 20209 | Mouse | Visual | 10 hr | 5 lux | - | ↑ | ↑ IL-6, NGF; ↑ PAG MOR | |
Blue 450–500nm | Noseda et al. 201676 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway |
Nir et al. 201875 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway | |
Khanna et al. 201947 | Rat | Visual | 8 hr | 4–5 lux | Functional pain syndromes | ↓ | Visual system → RVM | |
Green 500–565nm | Noseda et al. 201676 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↓ | - |
Ibrahim et al. 201743 | Rat | Visual | 8 hr | 4 lux | Chronic pain | ↓ | ↑ RVM descending pain
inhibition; ↓ CaV2.2 response; ↑ PENK; Naloxone reversal |
|
Khanna et al. 201947 | Rat | Visual | 8 hr | 4 lux | Chronic pain | ↓ | Visual system → RVM | |
Martin et al. 202068 | Human | Visual | 1–2 hr | 4–100 lux | Migraine | ↓ | - | |
Martin et al. 202067 | Human | Visual | 1–2 hr | 4–100 lux | Fibromyalgia | ↓ | - | |
Amber 590nm | Noseda et al. 201676 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway |
Nir et al. 201875 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway | |
Red 625–740nm | Stelian et al. 199296 | Human | Skin | 15 min | 8 mW/cm2 | Knee osteoarthritis | ↓ | - |
Hsieh et al. 201241 | Rat | Skin | 60 sec | 150 mW/cm2 | Neuropathic pain | ↓ | ↓ TNF-α, IL1-β, HIF-1α | |
Noseda et al. 201676 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway | |
Nir et al. 201875 | Human | Visual | 3 min | 1–100 cd/m2 | Migraine | ↑ | Retino-thalamo-cortical pathway | |
Langella et al. 201856 | Human | Skin | 300 sec | 16.66 mW/cm2 | Post-total hip arthroplasty | ↓ | ↓ serum IL-8, TNF-α, IL-6 | |
Khanna et al. 201947 | Rat | Visual | 8 hr | 50 lux | Functional pain syndromes | ↑ | Visual system → RVM | |
Pigatto et al. 202088 | Mouse | Skin | 60 sec | 84.64 mW/cm2 | - | ↓ | ↓ TRPA1, TRPV1, TRPM8, and ASIC receptor nociception | |
Herpich et al. 202038 | Human | Skin | 300 sec | 5 mW/cm2 | TMD | ↓ | - | |
Rodrigues et al. 202090 | Rat | Skin | 20 sec | 316 mW/cm2 | CRPS-I | ↓ | - | |
Near-Infrared (750–1000nm) | Stelian et al. 199296 | Human | Skin | 15 min | 11 mW/cm2 | Knee osteoarthritis | ↓ | - |
Cidral-Filho et al. 201315 | Mouse | Skin | 32 sec | 80 mW/cm2 | Neuropathic pain | ↓ | ↓ spinal cord + sciatic nerve TNF-α | |
Cidral-Filho et al. 201416 | Mouse | Skin | 153 sec | 80 mW/cm2 | Postoperative incisional pain | ↓ | ↑ activation peripheral opioid receptors | |
Martins et al. 201670 | Mouse | Skin | 50 sec | 80 mW/cm2 | Inflammatory pain | ↓ | ↑ IL-10; ↑ catalase; ↑ superoxide dismutase; ↓ TBARS | |
Holanda et al. 201739 | Rat | Skin | 120 sec | 300 mW/cm2 | Neuropathic pain | ↓ | ↓ signal via cytoskeletal disruption | |
Kobiela Ketz et al. 201749 | Rat | Skin | 19 sec | 43.25 mW/cm2 | Neuropathic pain | ↓ | ↑ M2 macrophage activation | |
Pigatto et al. 201787 | Mouse | Skin | 20 min | 17.3 mW/cm2 | - | ↓ | ↓ PKA, PKC activation | |
de Sousa et al. 201820 | Mouse | Skin | 120 sec | 50 mW/cm2 | Chronic peripheral pain | ↓ | ↓ DRG mGLuR1; ↑ PAP | |
Langella et al. 201856 | Human | Skin | 300 sec | 9.66 mW/cm2 | Post-total hip arthroplasty | ↓ | ↓ serum IL-8, TNF-α, IL-6 | |
Yadav et al. 2018103 | Rat | Skin | 10 min | 0.4 mW/cm2 | Burn wound | ↓ | ↓ TNF-α, NFκB, IL1-β, COX-2, substance-P receptor | |
Balbinot et al. 20195 | Rat | Skin | 40 sec | 1.43 mW/cm2 | Knee osteoarthritis | ↓ | ↓ spinal cord astrogliosis | |
Pigatto et al. 201989 | Mouse | Skin | 20 min | 17.4 mW/cm2 | CRPS-I, Neuropathic pain | ↓ | - | |
Rodrigues et al. 202090 | Rat | Skin | 40 sec | 316 mW/cm2 | CRPS-I | ↓ | - | |
Herpich et al. 202038 | Human | Skin | 300 sec | 5 mW/cm2 | TMD | ↓ | - |
Abbreviations: ASIC, acid-sensing ion channels; CaV2.2, N-type voltage-gated calcium channel; COX-2, cyclooxygenase-2; CRPS-I, complex regional pain syndrome-1; DRG, dorsal root ganglion; HIF-1α, hypoxia-inducible factor-1α; IL-1β, interleukin 1β; IL-6, interleukin 6; IL-8, interleukin 8; IL-10, interleukin 10; LBP, low back pain; mGLuR1, metabotropic glutamate receptor type 1; MOR, μ-opioid receptor; NFκB, nuclear factor kappa B; NGF, nerve growth factor; OPN, olivary pretectal nucleus; PAG, periaqueductal gray; PAP, prostatic acid phosphatase; PENK, proenkephalin-A; PKA, protein kinase A; PKC, protein kinase C; RVM, rostral ventromedial medulla; TBARS, thiobarbituric acid reactive species; TMD, temporomandibular disorder; TNF-α, tumor necrosis factor α; TRPA1, Transient Receptor Potential Ankyrin 1; TRPM8, Transient Receptor Potential Melastatin 8; TRPV1, Transient Receptor Potential Vanilloid 1.